Cardiovascular concerns are on the rise for people with diabetes, both in terms of acute and chronic complications, and a
A coordinated paradigm designed to overcome patient-, clinic-, and system-level barriers to care can significantly increase the prescribing of evidence-based
Retatrutide, a novel triple therapy, could continue the string of game-changing metabolic agents that began with semaglutide, a GLP-1 receptor
As part of the session “Where Lie the Keys to Type 2 Diabetes Prevention? Population Health or Personalized Medicine?”, This
As part of the session “Where Lie the Keys to Type 2 Diabetes Prevention? Population Health or Personalized Medicine?”, This
As part of the session “Are Two Better than One? Initial Combination Therapy in Type 2 Diabetes Mullites”, this paper
As part of the session “Are Two Better than One? Initial Combination Therapy in Type 2 Diabetes Mullites”, this paper
Today, the results of SURMOUNT-2, a trial of tirzepatide in participants with type 2 diabetes and obesity, were released, revealing
The American Diabetes Association® published the Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes in 2021, which
The results of the ongoing clinical trial of VX- 880, a phase 1/2, multi-center, single-arm, openlabel study in patients with